Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
| Autor: | Mills, Anthony M, Rizzardini, Giuliano, Ramgopal, Moti N, Osiyemi, Olayemi O, Bogner, Johannes R, Hagins, Debbie P, Paredes, Roger, Reynes, Jacques, Rockstroh, Jürgen K, Carr, Andrew, Su, Feng-Hsiu, Klopfer, Stephanie O, Eves, Karen, Plank, Rebeca M, Correll, Todd, Fox, Michelle C * |
|---|---|
| Zdroj: | In The Lancet HIV June 2024 11(6):e357-e368 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|